Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require therapeutic drug monitoring Safety aspects of AL001 development may qualify for a 505(b)(2) NDA pathway for FDA approval ATLANTA / Dec 11, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage... Read More

Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require therapeutic drug monitoring Safety aspects of AL001 development may qualify for a 505(b)(2) NDA pathway for FDA approval ATLANTA / Nov 20, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage... Read More

ATLANTA / Nov 16, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced that it has received a notification letter (the “ Compliance... Read More

Alzamend’s recently completed Phase IIA Study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require therapeutic drug monitoring Safety aspects of AL001 development may qualify for a 505(b)(2) NDA pathway for FDA approval ATLANTA / Nov 13, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage... Read More

ATLANTA / Oct 30, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced that Alzamend’s board of directors approved a... Read More

Safety aspects of AL001 development may qualify for a 505(b)(2) NDA pathway for FDA approval Alzamend recently completed a Phase IIA Study of AL001 in Alzheimer’s patients and healthy subjects showing a benign safety/ tolerability profile while characterizing dosing levels unlikely to require therapeutic drug monitoring ATLANTA / Oct 23, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a... Read More

Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects identified a candidate dose that is unlikely to require therapeutic drug monitoring Safety aspects of AL001 development may qualify for a Section (505)(b)(2) NDA pathway in support of FDA approval ATLANTA / Oct 02, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical... Read More

ATLANTA / Sep 22, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced that it received notice from the Nasdaq Hearings Panel (the “... Read More

Safety aspects of AL001 development may qualify for (505)(b)(2) pathway for FDA approval Alzamend’s recently completed a Phase IIA Study of AL001 in Alzheimer’s and healthy patients that identified a candidate dose that is unlikely to require therapeutic drug monitoring ATLANTA / Aug 30, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing... Read More

Topline data identifies maximum tolerated dose from Phase IIA multiple ascending dose study as assessed by an independent safety review committee Identified dose is unlikely to require lithium therapeutic drug monitoring Alzamend plans two Phase II clinical trials to investigate the safety and efficacy of AL001 for patients with mild to moderate Alzheimer’s disease Investigational new drug applications to be filed for AL001... Read More

Panel to be held on Tuesday, June 20, 2023 at 2:00 PM ET ATLANTA / Jun 13, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder, major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced that CEO Stephan... Read More

Ault Alliance Congratulates Alzamend Neuro on This Important and Historic Milestone in Clinical Drug Discovery and Development LAS VEGAS / Apr 04, 2023 / Business Wire / Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company (“ Ault Alliance ” or the “ Company ”), is proud to announce that Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”) has initiated its Phase I/IIA clinical trial for its... Read More

ATLANTA / Apr 03, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced the initiation of a phase I/IIA clinical trial for its immunotherapy vaccine... Read More

ATLANTA / Apr 03, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug... Read More

Topline data expected in June 2023 ATLANTA / Mar 22, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder, major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced the completion of the clinical... Read More

ATLANTA / Mar 16, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced financial results for the third quarter ended January 31, 2023 and provided an... Read More

Presentation on Thursday, February 2, 2023 at 10:30 a.m. ET ATLANTA / Jan 26, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder, major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced that it will be... Read More

Study to Assess the Safety, Tolerability, and Efficacy of Autologous Amyloid Beta Mutant Peptide-Pulsed Dendritic Cells (ALZN002) in Subjects With Mild-to-Moderate Dementia of the Alzheimer's Type Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder, major... Read More

Topline Data for Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s Expected in Second Quarter of 2023 Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder, major depressive disorder (“ MDD ”) and post-traumatic... Read More